Nature Biotechnology

Journal · Biotechnology · Updated 14 November 2026

Nature Biotechnology

Read Nature Biotechnology articles on DeepDyve. No university library needed.

Nature Biotechnology, which began as Bio/Technology, has published under its current title since 1996 on the tools and technologies of the life sciences, from genome editing and cell therapy to the computational methods that make sense of biological data. It is part of Springer Nature’s Nature Portfolio. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately. Personal plans aren’t for business use: reading for work? See Enterprise.

Cover of Nature Biotechnology
November 2026 issue

Nature Biotechnology at a glance

Full title
Nature Biotechnology
Former title
Bio/Technology
Abbreviation (NLM)
Nat Biotechnol
Publisher
Springer Nature (Nature Portfolio)
Print ISSN
1087-0156
Online ISSN (eISSN)
1546-1696
Current title since
1996
Subjects
Biotechnology
Access model
Hybrid: subscription, with an open access option
On DeepDyve
Research articles; availability varies by article

Ways to access Nature Biotechnology

17% of the articles Nature Biotechnology published from January 1 to November 13, 2026 are open access and free to read. For the rest, look for a preprint or the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 17% of Nature Biotechnology articles published from January 1 to November 13, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. Preprints. Nature Biotechnology encourages authors to post preprints of their research on servers such as arXiv or bioRxiv. A preprint can differ from the published paper.
  3. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Nature Biotechnology. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Nature Biotechnology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; Nature Portfolio preprint policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Nature Biotechnology’s 2025 Journal Impact Factor is 44.5, and its 5-year Impact Factor is 50.9.

44.5

Journal Impact Factor (2025)

50.9

5-year Impact Factor (2025)

23.109

SCImago Journal Rank (2025)

4 days

Median time to first editorial decision

185 days

Median time from submission to acceptance

17%

Articles published open access, Jan 1 to Nov 13, 2026

Source: Springer Nature journal metrics for Nature Biotechnology. Impact Factor from Clarivate Journal Citation Reports. Open access share: 71 of 410 articles published January 1 to November 13, 2026 carry a Creative Commons license, per Crossref.

Recent Nature Biotechnology research worth reading

Published June to October 2026. Summaries describe what the authors report.

  1. LitStreamImmunotherapy · Drug delivery

    In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles

    The authors build lipid nanoparticles that home in on natural killer cells, reporting up to about 80% transfection in mice, and show that delivering CAR mRNA this way makes CAR NK cells in the body that cleared circulating B cells, autoreactive T cells and tumors.

    Chen et al. · Nature Biotechnology, published online October 13, 2026 · DOI 10.1038/s41587-026-03310-1

  2. LitStreamAI · Computational biology

    Generalist biological artificial intelligence in modeling the language of life

    The authors review generalist biological artificial intelligence, models that read and generate DNA, RNA, proteins and cellular systems, and lay out the data, biological complexity, scaling and validation problems between today’s specialized models and systems that handle all of it at once.

    Nature Biotechnology, June 2026 · DOI 10.1038/s41587-026-03064-w

  3. LitStreamGenome editing

    Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells

    The authors retarget the serine integrase Bxb1 with a modular system they call MINT and report one-step insertion of large DNA at the human AAVS1 and TRAC sites, 29% and 35% efficiency in K562 cells, where the unmodified enzyme has no detectable activity.

    Nature Biotechnology, June 2026 · DOI 10.1038/s41587-026-03186-1

  4. LitStreamGenomics · Machine learning

    High-resolution reconstruction of cell-type-specific transcriptional regulatory processes from bulk sequencing samples

    The authors present DeepDETAILS, a deep learning method that separates bulk sequencing signals by cell type at base-pair resolution, and use it to build a compendium across 39 human tissues and 86 cell types and to fine-map risk variants for primary sclerosing cholangitis.

    Nature Biotechnology, July 2026 · DOI 10.1038/s41587-026-03218-w

  5. LitStreamMicrobiome · Synthetic biology

    Transferable genetic toolsets for nonmodel gut Clostridia enable in vivo reversible control of metabolite production

    The authors assemble transferable genetic tools for gut Clostridia that have resisted engineering, including strong promoters, an inducible system and CRISPR deletions, and use them to turn production of trimethylamine and deoxycholic acid on and off in mice.

    Nature Biotechnology, August 2026 · DOI 10.1038/s41587-026-03269-z

See every Nature Biotechnology article on DeepDyve

Questions about Nature Biotechnology

How can I read Nature Biotechnology articles without a subscription?

17% of Nature Biotechnology articles published from January 1 to November 13, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read Nature Biotechnology articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Nature Biotechnology?

Nature Biotechnology’s NLM (PubMed) abbreviation is Nat Biotechnol.

What is the ISSN of Nature Biotechnology?

The print ISSN is 1087-0156 and the online ISSN is 1546-1696.

Is Nature Biotechnology open access?

Nature Biotechnology is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 13, 2026, 71 of 410 Nature Biotechnology articles (17%) carry a Creative Commons license, per Crossref.

What is the impact factor of Nature Biotechnology?

Nature Biotechnology’s Journal Impact Factor is 44.5 (2025), and its 5-year Impact Factor is 50.9, according to Springer Nature’s published metrics.

Nature Biotechnology articles on DeepDyve are licensed from Springer Nature. Journal facts as of 14 November 2026.

Start reading Nature Biotechnology today

One month free, then less than $2 a day. Nature Biotechnology, plus millions of articles from thousands of journals.

Start free month